| |
January 9-10, 2024 | San Francisco, CA
January 16-18, 2024 | Virtual Don't miss this chance to position your company as an industry leader. Join over 500 senior pharma and biotech executives at this can't miss event! - Thought Leadership
- Branding - Networking
- Exhibit & Meeting Space Register today and Save $450!
|
|
Today’s Big NewsNov 21, 2023 |
| By Nick Paul Taylor BeiGene is buying its way into a cancer niche targeted by Bayer, Blueprint Medicines, Incyte and Pfizer, striking a backloaded, $1.33 billion deal for a global license to Ensem Therapeutics’ CDK2 inhibitor. |
|
|
|
By Nick Paul Taylor Jean-Paul Kress’ words are coming back to haunt him. The MorphoSys CEO has said AbbVie “failed” its phase 3 myelofibrosis trial because the Big Pharma missed one of two endpoints and stated regulators want to see hits on both measures. Now, Kress is defending MorphoSys’ similarly mixed data on its $1.7 billion rival. |
By James Waldron Merck & Co. has made no secret of its ongoing hunt for acquisitions, and, now, the Big Pharma is rounding off the year by swelling its preclinical pipeline with a selection of programs aimed Parkinson’s disease and beyond. |
Sponsored by Adaptive Biotechnologies Dr. Sharon Benzeno, Chief Commercial Officer of Immune Medicine at Adaptive Biotechnologies, shines a spotlight on the key immune-driven medicine advancements that show immense promise in transforming diagnoses, treatments, and patient outcomes. |
By James Waldron While a COVID-19 patent battle with Pfizer rumbles on, Enanta Pharmaceuticals has hit pause on development of a dual inhibitor for human metapneumovirus and respiratory syncytial virus in an effort to pave a cash runway into 2027. |
Sponsored by Cerba Research There were 250 decentralised clinical trials (DCTs) worldwide in 2012. By 2021, there were 1,291. Dan Tanner, chief commercial officer at Cerba Research, explains how the firm is helping to create a new paradigm in clinical trials. |
By Max Bayer New Flagship Pioneering biotech Quotient Therapeutics has lots to be thankful for this year, namely $50 million in cash, a new UK outpost to work from and a formal unveiling as the holiday season approaches. |
By Gabrielle Masson Simcere Pharmaceutical is paying Connect Biopharma $21 million upfront and offering up to $120 million in biobucks for the right to develop and commercialize Connect’s monoclonal antibody to treat certain inflammatory diseases in Greater China. |
By Joseph Keenan Global CRO Fortrea and life sciences software provider Medidata are teaming up to increase access for diverse patients to participate in clinical trials. |
By Andrea Park Labcorp is planning to lay off dozens of workers from a New Jersey facility by next spring, according to a recent filing with the state’s labor department in accordance with the federal Worker Adjustment and Retraining Notification Act. |
By Fraiser Kansteiner In a letter sent to Sanofi and AstraZeneca, Sen. Tammy Duckworth, D-Illinois, lamented that the drugmakers “seem to have vastly underestimated” the amount of Beyfortus—also known nirsevimab—needed to protect young kids during this year's RSV disease season. |
By Paige Minemyer The financial outlook for major health plans is stable in the face of notable potential headwinds heading into the end of the year. |
Fierce podcastsDon’t miss an episode |
| | This episode of "The Top Line" is dedicated to Alzheimer’s disease, spotlighting the latest treatments and what lies ahead. Fierce Pharma's Fraiser Kansteiner discusses Leqembi's full approval with Eisai's Alexander Scott. Annalee Armstrong from Fierce Biotech interviews Alzheimer's expert Howard Fillit, M.D., exploring groundbreaking research. Fierce Pharma’s Eric Sagonowsky speaks with Reisa Sperling, M.D., about Leqembi's potential in preventing Alzheimer’s progression before symptoms emerge. |
|
|---|
|
|
|
Tuesday, November 28, 2023 | 11am ET / 8am PT Elevate your biopharmaceutical game! Join our webinar to explore game-changing solutions. Uncover the power of Recombumin® rHA – the consistent, animal-free alternative revolutionizing manufacturing. Don't miss this chance to stay ahead in the advanced therapy landscape.
|
|
| WhitepaperAccelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperDownload our whitepaper to learn about plasmid DNA design considerations for cell and gene therapy applications. Sponsored by: Aldevron, a GMP manufacturing CDMO of DNA, RNA, and Proteins |
| WhitepaperThis paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
